To the full analysis
Addus HomeCare stock: growth
ADUSAddus HomeCare reported $1.42B in revenue for fiscal 2025, up 23.2% on the prior year, up 13.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
11.7%
per year from 2007 to 2025, per share −4.9%
Earnings (Annual rate)
41%
per year from 2007 to 2025
Free cash flow (Annual rate)
22.5%
per year from 2007 to 2025, per share 4.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2007 | |
|---|---|---|---|
| Revenue | 13.2% | 15.5% | 11.7% |
| Revenue per share | 9.8% | 9.8% | −4.9% |
| Earnings | 23.7% | 23.5% | 41.0% |
| Earnings per share | 19.6% | 17.3% | no data |
| Free cash flow | 0.2% | 50.4% | 22.5% |
| Free cash flow per share | −2.8% | 43.0% | 4.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $194.57M | $197K | $2.7M |
| 2008 | $236.31M | $4.02M | $4.2M |
| 2009 | $259.31M | $3.6M | −$9.6M |
| 2010 | $271.73M | $6.03M | $10.09M |
| 2011 | $273.1M | −$1.98M | $15.4M |
| 2012 | $244.32M | $7.64M | $14.29M |
| 2013 | $265.94M | $19.15M | $26.51M |
| 2014 | $312.94M | $12.24M | $1.7M |
| 2015 | $336.82M | $11.62M | $1.75M |
| 2016 | $400.69M | $12.02M | −$2.46M |
| 2017 | $425.72M | $13.61M | $49.16M |
| 2018 | $518.12M | $17.5M | $27.85M |
| 2019 | $648.79M | $25.24M | $7.4M |
| 2020 | $764.78M | $33.13M | $102.58M |
| 2021 | $864.5M | $45.13M | $34.84M |
| 2022 | $951.12M | $46.03M | $96.81M |
| 2023 | $1.06B | $62.52M | $102.79M |
| 2024 | $1.15B | $73.6M | $110.38M |
| 2025 | $1.42B | $95.91M | $103.79M |
Revenue by segment
How Addus HomeCare Corporation makes its money and how that has shifted. Names are as the company reports them.
- Personal Care77%
- Hospice18%
- Home Health5%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Personal Care | $794.72M | $856.58M | $1.09B | 76.6% |
| Hospice | $207.16M | $228.19M | $262.54M | 18.5% |
| Home Health | $56.78M | $69.83M | $70.77M | 5% |
| Total revenue | $1.06B | $1.15B | $1.42B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.